CRBU
NASDAQCaribou Biosciences Inc.
Price$2.00-0.22 (-9.91%)
01:30 PM07:45 PM
News · 26 weeks36-57%
2025-12-072026-05-31
Mix1390d
- Other7(54%)
- SEC Filings6(46%)
Latest news
25 items- PRCaribou Biosciences to Participate in the 2026 Jefferies Global Healthcare ConferenceBERKELEY, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:35pm ET in New York. For more information and a link to the webcast, visit the Events page on Caribou's website. Webcasts will be available on the Caribou website for at least 30 days after the event. About Caribou Biosciences, Inc.Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing tr
- PRCaribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor ConferenceBERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Caribou's management team will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, at 12:30pm ET in New York, New York. For more information and a link to the webcast, visit the Events page on Caribou's website. Webcasts will be available on the Caribou website for at least 30 days after the event. About Caribou Biosciences, Inc.Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative th
- PRCaribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual MeetingBERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for oral presentations at the 2026 European Hematology Association (EHA) Annual Meeting, which will be held June 11-14, 2026, in Stockholm, Sweden. The first oral presentation will highlight the long-term durability of a single dose of vispa-cel in patients enrolled in the ANTLER phase 1 clinical trial for relapsed or refractory B cell non-Hodgkin lymphoma. Details of the ANTLER phase 1 presentation are as follows: Title: Vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy w
- SECSEC Form 10-Q filed by Caribou Biosciences Inc.10-Q - Caribou Biosciences, Inc. (0001619856) (Filer)
- SECCaribou Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Caribou Biosciences, Inc. (0001619856) (Filer)
- PRCaribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL -- -- Longer follow up on vispa-cel phase 1 clinical data expected at medical conference in 2026 -- -- CaMMouflage phase 1 trial evaluating CB-011 continues to enroll r/r MM patients, dose escalation and expansion clinical data updates expected in 2026 -- BERKELEY, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the first quarter of 2026 and provided a business update. "We are pleased to have aligned with the FDA on the pivotal ANTLER-3 trial design for vi
- PRCaribou Biosciences to Participate in the BofA Securities 2026 Health Care ConferenceBERKELEY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at BofA Securities 2026 Health Care Conference on May 13, 2026, at 8:40am PT in Las Vegas, Nevada. For more information and a link to the webcast, visit the Events page on Caribou's website. Webcasts will be available on the Caribou website for at least 30 days after the event. About Caribou Biosciences, Inc.Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developi
- SECSEC Form DEFR14A filed by Caribou Biosciences Inc.DEFR14A - Caribou Biosciences, Inc. (0001619856) (Filer)
- SECSEC Form DEFA14A filed by Caribou Biosciences Inc.DEFA14A - Caribou Biosciences, Inc. (0001619856) (Filer)
- SECSEC Form DEF 14A filed by Caribou Biosciences Inc.DEF 14A - Caribou Biosciences, Inc. (0001619856) (Filer)
- SECSEC Form PRE 14A filed by Caribou Biosciences Inc.PRE 14A - Caribou Biosciences, Inc. (0001619856) (Filer)
- SECCaribou Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Caribou Biosciences, Inc. (0001619856) (Filer)
- PRCaribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy-- RMAT granted based on promising initial clinical data, including previously disclosed recommended dose for expansion data of 92% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve r/r MM patient cohort -- -- Ongoing dose expansion enrollment in CaMMouflage phase 1 clinical trial includes BCMA-naïve and BCMA-exposed cohorts; initial dose expansion and longer follow up on dose escalation data expected in 2026 -- BERKELEY, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medi
- SECSEC Form S-8 filed by Caribou Biosciences Inc.S-8 - Caribou Biosciences, Inc. (0001619856) (Filer)
- SECSEC Form 10-K filed by Caribou Biosciences Inc.10-K - Caribou Biosciences, Inc. (0001619856) (Filer)
- SECCaribou Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Caribou Biosciences, Inc. (0001619856) (Filer)
- PRCaribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateBERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 2025 and provided an overview of recent corporate highlights. "2025 was a year of strong execution for Caribou as we advance two potentially best-in-class allogeneic CAR-T cell therapy programs," said Rachel Haurwitz, PhD, Caribou's president and CEO. "The vispa-cel ANTLER phase 1 data in second-line LBCL patients demonstrated efficacy and durability on par with autologous CAR-T therapy and solidified our confidence that this program is delivering on the prom
- INSIDERChief Technology Officer Kelly Timothy P sold $12,020 worth of shares (6,228 units at $1.93), decreasing direct ownership by 8% to 73,125 units (SEC Form 4)4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
- SECSEC Form 144 filed by Caribou Biosciences Inc.144 - Caribou Biosciences, Inc. (0001619856) (Subject)
- SECSEC Form 144 filed by Caribou Biosciences Inc.144 - Caribou Biosciences, Inc. (0001619856) (Subject)
- INSIDERChief Technology Officer Kelly Timothy P was granted 45,000 shares and sold $6,168 worth of shares (3,147 units at $1.96), increasing direct ownership by 112% to 79,353 units (SEC Form 4)4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
- INSIDERChief Legal Officer Mcclung Barbara G was granted 45,000 shares and sold $13,598 worth of shares (6,938 units at $1.96), increasing direct ownership by 9% to 481,564 units (SEC Form 4)4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
- INSIDERChief Business Officer Khan Ruhi Ahmad was granted 45,000 shares and sold $13,598 worth of shares (6,938 units at $1.96), increasing direct ownership by 57% to 104,998 units (SEC Form 4)4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
- INSIDERChief Medical Officer Albertson Tina M. was granted 55,000 shares and sold $2,089 worth of shares (1,066 units at $1.96), increasing direct ownership by 370% to 68,523 units (SEC Form 4)4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
- INSIDERSEC Form 4 filed by Director Richardson-Heron Dara4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
CRBU FAQ
6 questionsWhere does CRBU stock trade?
Caribou Biosciences Inc. (CRBU) is listed on NASDAQ.What sector and industry is CRBU in?
Caribou Biosciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Caribou Biosciences Inc. go public?
Caribou Biosciences Inc. (CRBU) completed its IPO in 2021.What are analysts saying about CRBU?
Caribou Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Evercore ISI: In-line with a $300.00 price target on 2024-06-03.What companies are similar to CRBU?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare CRBU side-by-side with any of them on Quantisnow.How can I track CRBU on Quantisnow?
Quantisnow aggregates Caribou Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRBU to receive live email and push alerts on every new disclosure.